Pammolli, Fabio and Riccaboni, Massimo and Oglialoro, Claudia and Magazzini, Laura and Baio, Gianluca and Salerno, Nicola (2005): Medical Devices Competitiveness and Impact on Public Health Expenditure. Published in: Entreprise Directorate-General, European Commission (2005)
Download (2MB) | Preview
This study provides an analytical overview of the state of the European Union medical device industry. The medical device industry sector encompasses an extremely large variety of products and technologies. It covers hundreds of thousands of products that range from more traditional products, such as bandages or syringes, to sophisticated devices that incorporate bioinformatics, nanotechnology and engineered cells. These are designed for use by practitioners, patients and healthy individuals in a variety of settings: hospitals, surgeries and private homes. Besides being a vital and innovative industry, medical devices are a key component of healthcare systems and represent, together with pharmaceuticals, the bulk of ‘medical technology’. The analysis of the sector must therefore investigate medical devices as an industry – an innovative contributor to the economy – as well its key input to healthcare systems. The following aspects are taken into account: a) the impact of innovation in medical devices on health costs and expenditure; b) the innovativeness of the European medical device industry; c) the competitiveness of the European medical device industry as compared to that of the United States and Japan.
|Item Type:||MPRA Paper|
|Original Title:||Medical Devices Competitiveness and Impact on Public Health Expenditure|
|Keywords:||healthcare expenditure; medical devices; competitiveness; innovation|
|Subjects:||H - Public Economics > H5 - National Government Expenditures and Related Policies > H51 - Government Expenditures and Health
I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy; Regulation; Public Health
|Date Deposited:||02. Sep 2009 14:22|
|Last Modified:||11. Feb 2013 21:42|
ADDE & FIDE, 2004: 2004 Survey on the European Dental Trade. ADDE, Berne.
AdvaMed, 2004: The Medical Industry at a Glance. Washington DC.
Advanced Technology Assessment Spa (ATA), 2004: ATA Database. Lucca.
American Diabetes Association, 2003: “Economic Costs of Diabetes in the US in 2002”. Diabetes Care 26, 917-932.
Arora A., Gambardella A., Pammolli F., Riccaboni M., 2001: “The Nature and the Extent of the Market for Technology in Biopharmaceuticals”. CNRS, Collection Les Cahiers de l’Innovation, Cahier n. 37.
Arrow K. J., 1983: Innovation in Large and Small Firms. In Ronen J. (ed.): Entrepreneurship. Lexington Books, Lexington, MA.
Arrow K., 1963: “Uncertainty and the Welfare Economics of Medical Care”. American Economic Review, 53,3, 941-73.
Baker L.C., 2001: “Managed Care and Technology Adoption in Health Care: Evidence from Magnetic Resonance Imaging”. Health Economics, 20, 395-421.
Baker L.C., Wheeler S.K., 1998: “Managed Care and Technology Diffusion: the Case of MRI”. Health Affairs, 17, 5, 195-207.
Barba Navaretti G., Venables A.J., 2004: Multinational Firms in the World Economy, Princeton University Press.
Barr N., 2001: The Truth about Pension Reforms. Finance and Development, 38 (3), September. International Monetary Fund, Washington, DC.
Bell D.S., Alele J., 1997: “Diabetic Ketoacidosis: Why Early Detection and Aggressive Treatment Are Crucial”. Postgraduate Medicine, 101:193-8, 203-4.
Bentkover J.D., Stewart E.J., Ignaszewski A., Lepage S. Et al., 2003: “New Technologies and Potential Cost Savings Related to Morbidity and Mortality Reduction in Class III/IV Heart Failure Patients in Canada”. International Journal of Cardiology, 88, 33-41.
Binder L., Schiel X., Binder C., Fernandes C. et al., 1998: “Clinical Outcome and Economic Impact of Aminoglycoside Peak Concentrations in Febrile Immunocompromised Patients with Hematologic Malignancies”. Clinical Chemistry, 44, 2, 408–414.
Blomqvist A.G., Carter R.A., 1997: “Is Health Care Really a Luxury?” Journal of Health Economics, 16, 207-229.
Blume S.S., 1992: Insight and Industry – On the Dynamics of Technological Change in Medicine. The MIT Press.
Botman S.L., Moore T.F., Moriarity C.L., Parsons V.L., 2000: Design and Estimation for the National Health Interview Survey, 1995-2004. Vital and Health Statistics, Series 2, Data from the National Health Survey.
Bradley T.B, Kominski G.F., 1992: “Contributions of Case Mix and Intensity Change to Hospital Cost Increases”. Health Care Financing Review, Winter, 14, 2, 151-163.
Braunschweig F., 2000: “Reduction of Hospital Days by Biventricular Pacing”. European Journal of Hearth Failure, 2, 399-406.
Briggs A., 1995: Handling Uncertainty in the Results of Economic Evaluation. Office of Health Economics, London.
Briggs A., Sculpher M.J., Buxton M.J., 1994: “Uncertainty in the Economic Evaluation of Health Care Technologies: the Role of Sensitivity Analysis”. Health Economics, 3, 95-104.
Bryan S., Buxton M., Brenna E., 2000: “Estimating the Impact of a Diffuse Technology on the Running Costs of a Hospital. A Case-Study of a Picture Archiving and Communication System”. International Journal of Technology Assessment in Health Care, 16:3, 787–798.
Canadian Erythropoetin Study Group. 1990: “Association between Recombinant Human Erythropoetin and Quality of Life and Exercise Capacity of Patients Requiring Haemodyalisis”. British Medical Journal. 300. 573.
CDC Diabetes Cost-Effectiveness Study Group, 1998: “The Cost-Effectiveness of Screening for Type 2 Diabetes”. Journal of the American Medical Association, 280, 1757-1763.
Center for Disease Control and Prevention, 2001: “Prevalence of Disabilities and Associated Health Conditions Among Adults, United States 1999”. Journal of the American Medical Association, 285, 12, 1571-1572.
Chai J.Y., 2000: “Medical Device Regulation in the United States and the European Union: A Comparative Study”, Food and Drug Law Journal, 55, 1, 57-80.
Chang, R., Pellisier, M., Hazen, G. 1998: “A Cost-Effectiveness Analysis of Total Hip Arthroplasty for Osteoarthritis of the Hip”. Journal of the American Medical Association. 275. 11.
Charnley, J., 1972: “The Long-Term Results of Low-Friction Arthroplasty of the Hip Performed as a Primary Surgery”. Journal of Bone and Joint Surgery. 54B. 61-76.
Chernew M., Fendrick A.M., Hirth R.A., 1997: “Managed Care and Medical Technology: Implications for Cost Growth”. Health Affairs, 16, 2, 196-206.
Cohen, D., Cosgrove, R., Berzin, R., et al. 2001: “Cost-Effectiveness of Eptifibadite in Patients Undergoing Planned Coronary Stenting: Results from the ESPRIT Trial”. Circulation. 104. Suppl. I., 386-387.
Conway S., 1993: “The Role of Users in the Innovation Process”. Doctoral Working Paper Series No 10(NS), Aston Business School.
Council of The European Union, 2003: Joint Report by the Commisison and the Council on Adequate and Sustainable Pensions, 7165/03, March. Bruxelles.
Credit Suisse First Boston, 2004: The Pulse – Medtech Quarterly Handbook. Americas/United States Medical Supplies & Devices, 7 July.
Crogham T.W., Pittman P.M., 2004: “The Medicine Cabinet: What’s in It, and Can We Change the Contents?”. Health Affairs, 23, 1, 23-33.
Cromwell J., Butrica B., 1995: “Hospital Department Cost and Employment Increases: 1980-92”. Health Care Financing Review, Fall, 147-166.
Curnis A., 2003: “Economic Evaluation of Biventricular Resynchronization in Patients with Moderate-Advanced Hearth Failure”. PharmacoEconomics, 5(1), 11-22.
Cutler D.M., McClellan M., Newhouse J.P., Remler D., 1998: “Are Medical Prices Declining? Evidence from Heart Attack Treatments”. Quarterly Journal of Economics, 113,4, 991-1024.
Cutler D.M., Sheiner L., 1998: “Managed Care and the Growth of Medical Expenditures”. In Garber A.M. (ed.), 1998: Frontiers of Health Policy Research, Vol. I. The MIT Press, Cambridge, Mass.
Cutler D. McClellan M., Newhouse J.P., 1999: “The Costs and Benefits of Intensive Treatment for Cardiovascular Disease”, in Triplett J. (ed.): Measuring the Prices of Medical Services. The Brookings Institution, Washington DC.
Cutler D.M, McClellan M., 2001: “Is Technological Change in Medicine Worth It?” Health Affairs, 20, 5, 11-29.
Cutler D.M., Huckman R.S., 2003: “Technological Development and Medical Productivity: the Diffusion of Angioplasty in New York State”. Journal of Health Economics, 22, 187-217.
Dahler-Eriksen B.S., Lauritzen T., Lassen J.F., Lund E.D., Brandslund I., 1999: “Near-Patient Test for C-Reactive Protein in General Practice: Assessment of Clinical, Organizational, andEconomic Outcomes”. Clinical Chemistry, 45,4, 478–485.
Danzon P.M., Pauly M.V., 2001: “Insurance and Technology: from Hospital to Drugstore”. Health Affairs, 20, 5, 86-100.
Danzon P.M., Nicholson S., Pereira N.S., 2003: “Productivity in Pharmaceutical-Biotechnology R&D: the Role of Experience and Alliances”. NBER Working Paper 9615.
Dasgupta P., David P.A., 1984: “Toward a New Economics of Science”. Research Policy, 23, 487- 521.
Datamonitor, 2003a: Global Health Care Equipment & Supplies. Datamonitor, London.
Datamonitor, 2003b: Orthopedics – Europe. Datamonitor, London.
Dernis H., Khan M., 2004: Triadic Patent Family Methodology. STI Working Paper Series, DSTI/DOC(2004)2.
DeWitt D., Hirsh I. 2003: “Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review”. Journal of the American Medical Association, 289, 2254–2264.
Di Matteo L., 2005: “The Macro Determinants of Health Expenditure in the United States and Canada: Assessing the Impact of Income, Age Distribution and Time”. Health Policy, 71, 23-42.
Diabetes Control and Complications Trial Research Group (DCCT) 1993: “The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long–Term Complications in Insulin–Dependent Diabetes Mellitus”. New England Medical Journal, 329, 977–985.
Diamond P., 2002: Towards an Optimal Social Security Design. CeRP Working Papers, April. Torino.
Dixit A., Pindyck R., 1996: Investment Under Uncertainty. Princeton University Press, Princeton, NJ.
Dixon T., Shaw M., Ebrahim S., Dieppe P., 2004: “Trends in Hip and Knee Joint Replacement: Socio Economic Inequalities and Projections of Needs”. Ann Rheum Diseases, 63, 825-830.
Docteur E., Oxley H., 2003: Health-Care Systems: Lessons from the Reform Experience. OECD Health Working Papers, 9.
Donabedian A., 1988: “The Quality of Care: How Can it be Assessed”. Journal of American Medical Association 260 (12): 1743 – 8.
Dosi G., 1982, “Technological Paradigms and Technological Trajectories: a Suggested Interpretation of the Determinants and Directions of Technical Change”. Research Policy, 11, 3, 147-162.
Dosi G., 1988: “Sources, Procedures and Microeconomic Effects of Innovation”. Journal of Economic Literature, 26, 1120-1171.
Dranove D., Weisbrod B., 1998: "A Survey of Medical R&D: Implications for the Future of Health Care Costs and Quality". Working Paper, Northwestern University, Department of Economics and Kellogg Graduate School of Management.
Drummond M., O’Brien B., Stoddart G., Torrance W., 1997: Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK.
EDMA, 2004: European IVD market Estimates 2003. Edma, Bruxelles.
Eucomed, 2003: Industry Profile 2003. Eucomed, Bruxelles.
Eucomed, 2004: Medical Technology Brief. Eucomed, Bruxelles.
European Union Economic Policy Committee, 2001: Budgetary Challenges Posed by Ageing Populations. The Impact on Public Spending on Pensions, Health and Long-term Care for the Elderly and Possible Indicators of the Long-run Sustainability of Public Finances (EPC/ECFIN/655/01-EN final). October, Bruxelles.
European Union Economic Policy Committee, 2003: The Impact of Ageing Populations on Public Finances: Overview of Analysis Carried out at EU Level and Proposals for a Future Work Program (EPC/ECFIN/435/03-EN final). October, Bruxelles.
Eurostat, 2004a: NewCronos, the Eurostat’s Reference Database.
Eurostat, 2004b: ComExt: Intra- and Extra-EU Trade.
Evans J., MacDonald T., Leese G., Ruta D., Morris A., 2000: “Impact of Type 1 and Type 2 Diabetes on Patterns of Costs of Drugs Prescribing: a Population Based Study”. Diabetes Care 23, 770– 774.
Feldstein M., 1971: “Hospital Cost Inflation: a Study of nonprofit price dynamics”. American Economic Rewiew, 61, 853-872.
Feldstein M., 1977: “Quality Change and the Demand for Hospital Care”. Econometrica, 45, 1681- 1702.
Feldstein M., Friedman B., 1977: “Tax Subsidies, the Rational Demand for Insurance, and the Health Care Crisis”. Journal of Public Economics, 7(2), 155-178.
Feldstein M., 1995: “The Economics of Health and Health Care: What Have We Learned? What Have I Learned?” American Economic Association Papers and Proceedings, May 1995, 28-31.
Feldstein M., Liebman J.B., 2001: Social Security. NBER Working Paper 8451. Cambridge, MA.
Fitzpatrick R., Lodge M., Shortall E., Dawson J., Sculpher M., Carr A., et al. 1998: Primary Total Hip Replacement Surgery: a Systematic Review of Outcomes and Modelling of Cost- Effectiveness Associated with Different Prostheses. Health Technology Assessment 2 no. 20.
Fuchs V.R., 1996: “Economic Values, and Health Care Reform”. American Economic Review, 8,1, 1- 24.
Fuchs V.R., 1999: “Health Care for the Elderly: How Much? Who Will Pay For It?” Health Affairs, 18, 1, 11- 21.
Fuchs V.R., Sox H.C., 2001: “Physicians’ Views of the Relative Importance of Thirty Medical Innovations”. Health Affairs, 20, 5, 30-42.
Furnes O., Espehaug B., Lie S., Engesaeter L., Vollset S., Hallan G., et al., 2005: Prospective Studies of Hip and Knee Prostheses – the Norwegian Arthroplasty Register 1987 – 2004. Scientific Exhibit presented at the 72nd Annual Meeting of the American Academy of Orthopaedic Surgeons, February 23-27, Washington, DC, USA.
Garattini L., Tediosi F., Chiaffarino F., Roggeri D., Parazzini F., Coscelli C., Gruppo di Studio Rilevazione Economica dei Costi e Risorse nel Diabete, 2001: “The Outpatient Cost of Diabetes Care in Italian Diabetes Centers”. Value in Health, 4: 251-7.
Gelijns A., Rosenberg N., 1994: “The Dynamics of Technological Change in Medicine”. Health Affairs, Summer 1994, 28-46.
Gerdtham U.G., Jonsson B., 2000: International Comparisons of Health Expenditure: Theory, Data and Econometric Analysis. In Culyer A.J., Newhouse J.P. (ed.): Handbook of Health Economics, Vol.1. Elsevier Science.
Ginsburg P.B., 2004: “Controlling Health Care Costs”. New England Journal of Medicine, 351, 16, 1591-1593.
Ginzberg E., 1990: “High-Tech Medicine and Rising Health Care Costs”. JAMA - Journal of the American Medical Association, 263, 13, 1820-1822.
Goddeeris J.H., 1984: “Insurance and Incentives for Innovation in Medical Care”. Southern Economic Journal, 51, 530-539.
Goddeeris J.H., 1987: “Economic Forces and Hospital Technology”. International Journal of Technology Assessment in Health Care, 3, 223-240.
Goetghebeur M.M, Forrest S. Hay J.W, 2003: “Understanding the Underlying Drivers of Inpatient Cost Growth: a Literature Review”. The American Journal of Managed Care, June, 3-12.
Goldsmith J., 1994: “The Impact of New Technology on Health Costs”. Health Affairs, Summer 1994, 80-81.
Goldstein D., Little R., Lorenz R., Malone J., Nathan D., Peterson C., 2004: “Tests of Glycemia in Diabetes”. Diabetes Care. 27(Suppl 1), S91–3.
Greenberg, D., Bakhai, A., Cohen, D., 2004: “Can We Afford to Eliminate Restenosis? Can We Afford not to?” Journal of American College of Cardiology. 43, 513-518.
Griliches Z., 1984: R&D, Patents and Productivity. University of Chicago Press.
Griliches Z., 1990: “Patents Statistics as Economic Indicators”. Journal of Economic Literature, 92, 630-653.
Hall B., Jaffe A., Trajtenberg M., 2001a: “Market Value and Patent Citations: A First Look”. UC Berkeley, Department of Economics, Working Paper No. E01-304.
Hall B., Jaffe A., Trajtenberg M., 2001b: The NBER Patent Citations Data File: Lessons, Insights And Methodological Tools. NBER Working Paper 8498.
Harhoff D.F., Narin F., Scherer F.M., Vopel K., 1999: “Citation Frequency and the Value of Patented Inventions”. Review of Economics and Statistics, 81, 3, 511-515.
Harris R., Lux L., Bunton A., Sutton S., Lohr K. et al. 2002: “Screening for Type 2 Diabetes Mellitus”. Systematic Evidence Review No. 19.
Havelin L., Engasaeter L., Espehaug B., Furnes O., Lie S., Vollset, S., 2000: “The Norwegian Arthroplasty Register: 11 Years and 73,000 Arthroplasties”. Acta Orthopaedica Scandinavia 71, 337-353.
Hay J.W., 2003: “Hospital Cost Drivers: An Evaluation of 1998–2001 State-Level Data”. The American Journal of Managed Care, June, 13-24.
Healthcare Industries Task Force, 2004: “Better Health Through Partnership: a Programme for Action”. Department of Health, London (UK).
Heymann S.J., Brewer T.F., Ettling M., 1997: “Effectiveness and Cost of Rapid and Conventional Laboratory Methods for Mycobacterium Tuberculosis Screening”. Public Health Reports, 112, 6, 513-523.
Higson G. R., 2002: “Medical Device Safety: The Regulation of Medical Devices for Public Health and Safety”, Institute of Physics Publishing, Bristol.
Hill S.C., Wolfe B. L., 1997: “Testing the HMO Competitive Strategy: An Analysis of its Impact on Medical Resources”. Journal of Health Economics, June 1997, 261-286.
Hill, R., Bagust, A., Bakhal, A., Dickson, R., et al. 2004: Coronary Artery Stents: a Rapid Systematic Review and Economic Evaluation. Health Technology Assessment NHS R&D HTA Programme, London, U.K.
Hirshfeld J., Wilensky R., 2004: “Drug-Eluting Stents Are Here – Now What? Implications for Clinical Practice and Health Care Costs”. Cleveland Clinic Journal of Medicine, 71, 825-828.
Holahan J., Dor A., Zuckerman S., 1990: “Understanding the Recent Growth in Medicare Physician Expenditures”. Journal of the American Medical Association, 263, 1658-1661.
Huber M., Orosz E., 2003: “Health Expenditure Trends in OECD Countries, 1990-2001”. Health Care Financing Review, 25,1, 1-22.
Ikegami N., Creighton Campbell J., 2004: “Japan’s Health Care System: Containing Costs and Attempting Reform”. Health Affairs, 3, 26-36.
Institute of Medicine – National Research Council, 2001: Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer. Washington DC.
International Diabetes Federation, 2004: Diabetes Atlas. International Diabetes Federation, Bruxelles, Belgium.
Jaffe A., Trajtenberg M., Fogarty M., 2000: The Meaning of Patent Citations: Report on the NBER/Case-Western Reserve Survey of Patentees, NBER Working Paper 7631.
Kahn A., 1991, The Dynamics of Medical Device Innovation: An Innovator’s Perspective. in A.C. Gelijns, A. Halm (eds.), The Changing Economics of Medical Technology. National Academy Press, Washington DC.
Kane N.M., Manoukian P.D., 1989: “The Effect of the Medicare Prospective Payment System on the Adoption of New Technology. The Case of Cochlear Implants”. New England Journal of Medicine, 321, 20, November 16, 1378-1383.
Katz S.J., Welch W.P., Verrilli D., 1997: “The Growth of Physician Services for the Elderly in the United States and Canada: 1987-1992”. Medical Care Research and Review, 54, 300-319.
Kleinknecht A., Van Montfort K., Brouwner E., 2002: “The Non-Trivial Choice between Innovation Indicators”. Economics of Innovation and New Technology, 11(2), 109-121.
Koenig L., Siegel J.M., Dobson A., Hearle K. et al., 2003: “Drivers of Healthcare Expenditures Associated with Physician Services”. American Journal of Managed Care, June, 34-42.
Lanjouw J.O., Schankerman M., 1999: The Quality of Ideas: Measuring Innovation with Multiple Indicators. NBER Working Paper 7345
LaPorte, D., Mont, M., Hungerford, D., 1999: “Proximally Porous-Coated Ingrowth Prostheses: Limit of Use”. Orthopaedics. 22. 1154-1160.
Larsen G. Hallstrom A., McAnulty J., Pinski S. et al., 2002: “Cost-Effectiveness of Implantable Cardioverter Defibrillator – Defibrillator versus Antiarrhythmic Drugs in Survivors of Serious Ventricular Tachyarrhythmia”. Circulation , 105, 2049-2057.
Legorreta A.P., Silber J.H., Costantino G.N. et al., 1993: “Increased Cholecystectomy Rate after the Introduction of Laparoscopic Cholecystectomy”. Journal of the American Medical Association, 270, 1429-1432.
Lemos P., Serruys P., Sousa E. 2003 : “Drug-Eluting Stents. Cost Versus Clinical Benefit”. Circulation, 107, 3003-3007.
Lenhard, M., Reeves, G., 2001: “Continuous Subcutaneous Insulin Infusion: a Comprehensive Review of Insulin Pump Therapy”. Archives of Internal Medicine, 161, 2293–2300.
Leon M., Moses J., Popma J., et al. 2002: “A Multicenter Randomized Clinical Study of the Sirolimus-Eluting Stent in Native Coronary Lesions: Angiographic Results”. Circulation. 106, Suppl. II, II-393.
Lichtenberg F., Virabhak S., 2003: Using Patents Data to Map Technical Change in Health-Related Areas. STI Working Paper Series, DSTI/DOC(2002)16.
Linkeschova R., Raoul M., Bott U., Berger M., Spraul M. 2002: “Less Severe Hypoglycaemia, Better Metabolic Control, and Improved Quality of Life in Type 1 Diabetes Mellitus with Continuous Subcutaneous Insulin Infusion (CSII) Therapy; an Observational Study of 100 Consecutive Patients Followed for a Mean of 2 Years”. Diabetic Medicine, 19(9), 746–51.
Lubitz J., Greenberg L.G., Gorina Y., Wartzman L., Gibson D., 2001: “Three Decades of Health Care Use by the Elderly”. Health Affairs, 20(2), 19-32.
Lucht, U., 2000: “The Danish Hip Arthroplasty Register”. Acta Orthopaedica Scandinavia. 71. 433- 439.
Lynd L, O’Brien BJ., 2003: “Cost-Effectiveness of Implantable Cardioverter Defibrillator: A Review of Current Evidence”. Journal of Cardiovascular Electrophysiology, 14 (9), S99-S103.
Mayes C.E., Kandzari D.E., Goldschmidt-Clermont P.J., Phillips H.R., 2002: “The Complementary Use of Glycoprotein IIb/IIIa Inhibitors and Drug-Eluting Stents in Contemporary Percutaneous Coronary Intervention”. Journal of Invasive Cardiology, 14, December, Suppl E, 36E-46E.
Meara E., White C., Cutler D.M., 2004: “Trends in Medical Spending by Age: 1963-2000”. Health Affairs, 23,4, 176-183.
Miles D., Sefton J., 2002: Optimal Social Security Design. CeRP Working Papers, March. Torino.
Miles D., Cerny A., 2006: Risk, Return an Portfolio Allocation under Alternative Pension Systems with Incomplete and Imperfect Financial Markets. Forthcoming in the Economic Journal.
Ministry of Health, Labor and Welfare, 2003: 2002 Annual Report for Research on the Actual Conditions of Medical device industry. Health Policy Bureau, Tokyo, Japan.
Ministry of Health, Labor and Welfare, 2004: 2003 Annual Report for Statistical Production Trend of Pharmaceutical Affairs Industry. Health Policy Bureau, Tokyo, Japan.
Modigliani F., Muralidhar A., 2004: Rethinking Pension Reforms. Cambridge University Press.
Morgan Stanley, 2004: Hospital Supplies and Medical Technology. Industry Equity Research – North America, July.
Murphy S., 1998: Does New Technology Increase of Decrease Health Care Costs? The Treatment of Peptic Ulceration. Journal of Health Services Research & Policy, 3,4, October.
Murray D., Carr A., Bulstrode C., 1995: “Which Primary Total Hip Replacement?” Journal of Bone and Joint Surgery, 77B, 520-527.
National Kidney Foundation, 2005: Foundation website, www.kidney.org (accessed April 2005).
Neumann P.J., Weinstein M.C., 1991: The Diffusion of New Technology: Costs and Benefits to Health Care. In Gelijns A.C., Halm A. (ed.), 1991: Medical Innovation at the Crossroads, Vol.2: The Changing Economics of Medical Technology. National Academy Press, Washington DC.
Newhouse J.P., 1992: “Medical Care Costs: How Much Welfare Loss?” Journal of Economic Perspectives, 6, 3, 3-21.
O’Neill W., Leon M., 2003: “Drug-Eluting Stents. Cost Versus Clinical Benefit”. Circulation. 107, 3008-3011.
O’Shea K., Bale E., Murray P., 2002: Cost Analysis of Primary Total Hip Replacement. Irish Medical Journal. 95 (6).
OECD, 1998: Maintaining Prosperity in an Ageing World. Paris.
OECD, 2001: Net Social Expenditure. Paris.
OECD, 2003: A Disease-Based Comparison of Health Systems: What is Best and at What Cost? Paris.
OECD, 2004: OECD Health Data 2004. OECD, Paris.
OECD, 2005: Pension at Glance – Public Policies across OECD Countries. Paris.
O'Hagan A., Stevens J.W., 2001: “A Framework for Cost-Effectiveness Analysis from Clinical Trial Data”. Health Economics 10, 302-315.
O'Hagan A., Stevens J.W., 2003: “Assessing and Comparing Costs: How Robust Are the Bootstrap and Methods Based on Asymptotic Normality?” Health Economics 12, 33-49.
Okunade A.A, Murthy V.N.R., 2002: “Technology as a ‘Major Driver’ of Health Care Costs: a Cointegration Analysis of the Newhouse Conjecture”. Journal of Health Economics, 21, 147-159.
Pammolli F. Oglialoro C., Salerno N., 2004: Strumenti di regolazione del mercato farmaceutico: un'analisi ragionata. Quaderno CERM 3/04, Luglio. Fondazione CERM, Roma.
Pammolli F., Salerno N.C., 2004: Le proiezioni di lungo termine della spesa sociale nell’UE: l’impatto demografico ed il possibile impatto della tecnologia sulla spesa sanitaria. Quaderni CERM, March 2004.
Parmigiani G., 2002: Modelling in Medical Decision Making: a Bayesian Approach. Wiley, Chichester.
Pauly M.V., 1968: “The Economics of Moral Hazard: Comment”. American Economic Review, 58(3), 531-37.
Pauly M.V., 1986: “Taxation, Health Insurance, and Market Failure in the Medical Economy”. Journal of Economic Literature, Vol. XXIV (June), 629-675.
Peden E.A., Freeland M.S., 1995: “A Historical Analysis of Medical Spending Growth, 1960-1993”. Health Affairs, 14,2, 235-247.
Peden E.A., Freeland M.S., 1998: “Insurance Effects on US Medical Spending (1960-1993)”. Health Economics, 7, 671-687.
Phelps C.E., 1973: The Demand for Health Insurance: A Theoretical and Empirical Investigation. Rand Corporation. Santa Monica, CA.
Phelps C.E., 2003: Health Economics. Pearson Addison Wesley, Boston, MA.
Pickup J., Mattock M., Kerry S., 2002: “Glycaemic Control with Continuous Subcutaneous Insulin Infusion Compared with Intensive Insulin Injections in Patients with Type 1 Diabetes: Meta– Analysis of Randomized Controlled Trials”. British Medical Journal, 324, 705–710.
PriceWaterhouseCoopers, 2002: The Factors Fueling Rising Healthcare Costs. Report prepared for the American Association of Health Plans.
Reikeras O., Gunderson R., 2003: “Excellent Results of HA Coating on a Grit-Blasted Stem”. Acta Orthopaedia Scandinavia, 72(2), 140-145.
Reinhardt U.E., Hussey P.S., Anderson G.F., 2002: “Cross-Comparison of Health Systems Using OECD Data, 1999”. Health Affairs, 21, 3, 169-181.
Reinhardt U.E., 2003: “Does the Aging of the Population Really Drive the Demand for Health Care?” Health Affairs, 22, 6, 27-39.
Reinhardt U.E., Hussey P.S., Anderson G.F., 2004: “US Health Care Spending in an International Context”. Health Affairs, May, Vol. 23, 3, 10-25.
Relman A.S., 1998: “Assessment and Accountability: the Third Revolution in Medical Care”. New England Journal of Medicine 319 (18): 1220 – 1222.
Rettig R.A., Levinsky N.G., 1991: Kidney Failure and the Federal Government. National Academy Press, Washington DC.
Rettig R.A., 1994: “Medical Innovation Duels Cost Containment”. Health Affairs, Vol. 13, 3, 7-27.
Rinfret S., Grines C., Grosove R. et al., 2001: “Quality of Life after Balloon Angioplasty or Stenting for Acute Myocardial Infarction: One-Year Results from the Stent-PAMI Trial”. Journal of American College of Cardiology, 38, 1614-1621.
Roberts E.B., 1987: Technological Innovation and Medical Devices. Paper presented at the National Academy of Engineering/Institute of Medicine - Symposium on New Medical Devices: Factors Influencing Invention, Development, and Use, March 9-10, Washington DC, USA.
Romeo A.A., Wagner J. L., Lee R.H., 1984: “Prospective Reimbursement and the Diffusion of New Technologies in Hospitals”. Journal of Health Economics, 3, 1, April 1984, 1-24.
Roze S., Valentine W., Zakrzewska K., Palmer A., 2005: Health Economic Comparison of Continuous Subcutaneous Insulin Infusion with Multiple Daily Injection for the Treatment of Type 1 Diabetes in the UK. Diabetes Care, forthcoming.
Russell L.B., 1979: Technology in Hospitals. Brooking Institute, Washington DC, USA.
Russell I., Grimshaw J., 1995: Health Technology Assessment: Basis of Valid Guidelines and Test of Effective Implementation? In Deighton M, Hitch S (ed.), Clinical Effectiveness from Guidelines to Cost-Effective Practice. Earlybird Publications, Brentwood.
Scherer F.M., 1965: “Firm Size, Market Structure, Opportunity, and the Output of Patented Inventions”. American Economic Review, 55, 5, 1097-1125.
Schumacher G.E., Barr J.T., 1998: “Economic and Outcome Issues for Therapeutic Drug Monitoring in Medicine”. Therapeutic Drug Monitoring, 20, 5, 539-542.
Schwartz W.B., 1987: “The Inevitable Failure of Current Cost-Containment Strategies. Why They Can provide Only Temporary Relief”. Journal of the American Medical Association, 257, 2, 220- 224.
Scitovski A.A., 1985: “Changes in the Cost of Treatment of Selected Illnesses, 1971-1981”. Medical Care, 23, 1345-1357.
Serruys, P., Degertekin M., Tanabe K., et al. 2002: “Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (Randomized Study of the Sirolimus-Eluting Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions) Trial”. Circulation, 106, 798-803.
SF36 Health Survey, 1994: “Scoring Maual for English Language Adaptions. Australia / New Zealand / Canada / United Kingdom”. Medical Outcomes Trust. 1-4.
Shactman D., Altman S.H., Eilat E., Thorpe K. E. et al, 2003: “The Outlook For Hospital Spending; Rapid Growth is Likely to Persist”. Health Affairs, 22(6), 12-26.
Shapiro I., Shapiro M., Wilcox D., 2001: Measuring the Value of Cataract Surgery. In Cutler D.M., Berndt E.R. (eds.) Medical Care Output and Productivity, University of Chicago Press, Chicago.
Shaw B., 1985: “The Role of the Interaction between the User and the Manufacturer in Medical Equipment Innovation”, R&D Management, 15, 4, 283-292.
Shearer A., Schuffham P., Mollon, P., 2004: “The Cost of Coronary Artery Disease in the UK”. British Journal of Cardiology. 11(3):218-223.
Sloan F., Valvona J., Perrin J.M., Adamache K.W., 1986: “Diffusion of Surgical Technology: an Exploratory Study”. Journal of Health Economics, 5, 31-61.
Standard & Poor’s, 2004a: Healthcare: Products & Supplies. Industry Surveys, September 2004.
Standard & Poor’s, 2004b: The Compustat® North America Database (accessed December 2004).
Taylor M.C., Greig P.D., Detsky A.S., McLeod R.S. et al., 2002: “Factors Associated with the High Cost of Liver Transplantation in Adults”. Canadian Journal of Surgery, December, 425-434.
TekPlus, 2002: PACS Market – North America and Western Europe. London.
The Economist, 2004: The Health of Nations. A Survey of Health-Care Finance. July 17.
The Economist, 2005: Health Care’s Outrageous IT Gap. April 30.
The Lewin Group, 1999: Outlook for Medical Technology Innovation: Will Patients Get the Care They Need? The Health Industry Manufacturer Association.
Thomasson M.A., 2002: “From Sickness to Health; the Twentieth-Century Development of U.S. Health Insurance”. Explorations in Economic History, 39, 233-253.
Trajtenberg M., 1990: “A Penny for your Quotes: Patent Citations and the Value of Innovations”. RAND Journal of Economics, 20, 172-187.
Trajtenberg, M., Henderson R., Jaffe A., 1997: “University vs. Corporate Patents: A Window on the Basicness of Innovations”. Economics of Innovation and New Technology, 5, 1, 19-50.
UK Prospective Diabetes Study (UKPDS) Group, 1998: “Intensive Blood Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes”. (UKPDS33). Lancet. 352. 837–853.
UK Prospective Diabetes Study (UKPDS) Group, 2002: “Implementing Intensive Control of Blood Glucose Concentration and Blood Pressure in Type 2 Diabetes in England: Cost Analysis”. (UKPDS63). British Medical Journal. 325.
United States Congress Office of Technology Assessment, 1984: Federal Policies and the Medical Device Industry. Washington, D.C.
United States Economic Report of the President 2004. United States Government Printing Office, Washington DC.
United States Food and Drug Administration, Center for Devices and Radiological Health, 2004a: 510(k) Database. Washington DC.
United States Food and Drug Administration, Center for Devices and Radiological Health, 2004b: PMA Database. Washington DC.
United States Food and Drug Administration, Center for Devices and Radiological Health, 2004c: Establishment Registration Database. Washington DC.
United States Food and Drug Administration, Center for Devices and Radiological Health, 2004d: Device Listing Database. Washington DC.
United States General Accounting Office (GAO), 1992: Hospital Costs – Adoption of Technologies Drives Cost Growth. Report to Congressional Requesters, September. Washington DC.
van Hout B., Lindeboom W., Morice M., 2002: “Cost-Effectiveness of the Sirolimus Eluting Bx- VELOCITY Stent: 1-Year Results”. European Heart Journal, 23, Suppl., 691.
Van Merode G.G., Adang E.M.M., Paulus A.T.G, 2002: Innovation in the Medical Device Industry. International Journal of Healthcare Technology and Management, 4, 5, 2002.
Vidalain J., ARTRO Group., 1999: “The Corail System in Primary THA”. European Journal of Orthopaedic Surgery and Traumatology, 9, 87-90.
von Hippel E., 1976, “The Dominant Role of Users in the Scientific Instrument Innovation Process”, Research Policy, 5, 3, 212-239.
Weaver W., Reisman M., Griffin J. et al, 2000: “Optimum Percutaneous Transluminal Coronary Angioplasty Compared with Routine Stent Strategy Trial (OPUS-1): a Randomised Trial”. Lancet, 335, 2199-2203.
Weintraub W., 2004: “Economics of Sirolimus-Eluting Stents. Drug-Eluting Stents have really arrived”. Circulation. 110, 472-474.
Weisbrod B.A., 1991: “The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care, and Cost-Containment”. Journal of Economic Literature, Vol. XXIX, 523-552.
Weisbrod B.A., LaMay C.L., 1999: “Mixed Signals: Public Policy and the Future of health Care R&D”. Health Affairs, 18, 2, 112-125.
Weissberg-Benchell J., Antisdel-Lomaglio J., Seshadri R., 2003: “Insulin Pump Therapy: a Meta Analysis”. Diabetes Care, 26, 1079–1087.
Wells, V., Hearn, T., McCaul, K., Anderton, S., Wigg, A., Graves, S., 2002: “Changing Incidence of Primary Total Hip Arthroplasty and Total Knee Arthroplasty for Primary Osteoarthritis”. Journal of Arthroplasty, 17. 267-263.
Wilensky G., 1990: “Technology as Culprit and Benefactor”. Quarterly Review of Economics and Business, 30,4, 45-53.
World Health Organisation, 2000: The Burden of Musculoskeletal Conditions at the Start of the New Millennium. Technical Report Series – 919, WHO, Geneve.
World Health Organization, 2002: The World Health Report Annexes. http://www.who.int/whr/2002/annex/en/ (accessed September 22, 2004).
World Health Organization, 2003: Medical Device Regulations: Global Overview and Guiding Principles, Geneva.
World Health Organization, 2004a: Cardiovascular Disease. http://www.who.int/cardiovascular_diseases/en/ (accessed September 22, 2004).
World Health Organization, 2004b: The Diabetes Programme. http://www.who.int/diabetes/en/ (accessed September 22, 2004).
Zweifel P., Felder S., Meiers M., 1999: “Ageing of the Population and Health Care Expenditure: a Red Herring?” Health Economics, 8, 485–496.